Medpace Inc. (MEDP)
NASDAQ: MEDP
· Real-Time Price · USD
294.83
1.80 (0.61%)
At close: May 23, 2025, 3:59 PM
295.82
0.34%
After-hours: May 23, 2025, 05:45 PM EDT
Medpace Revenue Breakdown
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|
| Antiviral And Anti Infective Revenue | 156.46M | 163.31M | 118.03M | 110.98M | 86.39M | 76.74M |
| Antiviral And Anti Infective Revenue Growth | -4.20% | +38.36% | +6.36% | +28.46% | +12.58% | n/a |
| Cardiology Revenue | 230.45M | 193.69M | 174.63M | 119.69M | 91.26M | 91.82M |
| Cardiology Revenue Growth | +18.98% | +10.91% | +45.90% | +31.16% | -0.62% | n/a |
| Central Nervous System Revenue | 181.98M | 160.06M | 157.94M | 121.55M | 65.39M | 53.9M |
| Central Nervous System Revenue Growth | +13.70% | +1.34% | +29.94% | +85.88% | +21.31% | n/a |
| Metabolic Revenue | 457.54M | 376.84M | 244.68M | 159.9M | 138.65M | 94.13M |
| Metabolic Revenue Growth | +21.41% | +54.01% | +53.02% | +15.33% | +47.30% | n/a |
| Oncology Revenue | 651.24M | 587.1M | 467.8M | 362.85M | 256.77M | 189.03M |
| Oncology Revenue Growth | +10.92% | +25.50% | +28.92% | +41.31% | +35.84% | n/a |
| Other Revenue | 431.38M | 404.84M | 296.91M | 267.42M | 222.51M | 161.19M |
| Other Revenue Growth | +6.56% | +36.35% | +11.03% | +20.18% | +38.04% | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 57.9M | 45.43M | 49.22M | 41.45M | 44.08M | 42.51M | 41.41M | 39.4M | 38.03M | 33.4M | 35.42M | 33.22M | 29.37M | 27.66M | 28.05M | 26.97M | 25.74M | 22.38M | 22.8M | 21.86M | 25.12M | 21.26M | 29.12M | 23.56M | 21.31M | 20.57M | 18.61M | 20.51M | 16M | 16.84M | 16.61M | 14.76M | 15.15M | 16.78M | 16.39M | 14.82M | 13.51M | 18.25M | 15.29M | 11.71M | 11.74M |
| Selling, General, and Administrative Revenue Growth | +27.43% | -7.69% | +18.73% | -5.96% | +3.69% | +2.67% | +5.08% | +3.62% | +13.85% | -5.69% | +6.63% | +13.11% | +6.15% | -1.36% | +3.98% | +4.80% | +15.00% | -1.82% | +4.31% | -13.01% | +18.17% | -26.99% | +23.62% | +10.55% | +3.59% | +10.55% | -9.27% | +28.18% | -5.01% | +1.42% | +12.54% | -2.63% | -9.71% | +2.39% | +10.57% | +9.73% | -26.00% | +19.35% | +30.66% | -0.31% | n/a |
| Research and Development Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Research and Development Revenue Growth | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |